• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    5/3/24 12:31:47 PM ET
    $AEON
    $ALHC
    $ALLR
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $AEON alert in real time by email

    Gainers

    • Eliem Therapeutics (NASDAQ:ELYM) shares moved upwards by 32.8% to $11.14 during Friday's regular session. The market value of their outstanding shares is at $308.8 million.
    • Ardelyx (NASDAQ:ARDX) shares rose 26.5% to $8.59. The market value of their outstanding shares is at $2.0 billion. The company's, Q1 earnings came out yesterday.
    • Twist Bioscience (NASDAQ:TWST) stock increased by 25.81% to $40.27. The company's market cap stands at $2.3 billion. The company's, Q2 earnings came out yesterday.
    • Tandem Diabetes Care (NASDAQ:TNDM) shares moved upwards by 25.62% to $45.93. The company's market cap stands at $2.9 billion. The company's, Q1 earnings came out yesterday.
    • Alignment Healthcare (NASDAQ:ALHC) shares increased by 24.61% to $6.55. The market value of their outstanding shares is at $1.2 billion. As per the news, the Q1 earnings report came out yesterday.
    • Syra Health (NASDAQ:SYRA) shares rose 22.5% to $1.47. The market value of their outstanding shares is at $9.7 million.

    Losers

    • Mobile-health Network (NASDAQ:MNDR) shares decreased by 73.8% to $5.78 during Friday's regular session. The market value of their outstanding shares is at $196.5 million.
    • AEON Biopharma (AMEX:AEON) stock fell 53.58% to $1.56. The company's market cap stands at $59.4 million.
    • CG Oncology (NASDAQ:CGON) stock decreased by 21.52% to $31.0. The company's market cap stands at $2.0 billion.
    • Owens & Minor (NYSE:OMI) stock fell 21.02% to $19.36. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q1 earnings came out today.
    • Allarity Therapeutics (NASDAQ:ALLR) shares fell 17.08% to $1.02. The market value of their outstanding shares is at $1.9 million.
    • Nuwellis (NASDAQ:NUWE) shares declined by 13.69% to $0.18. The company's market cap stands at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEON
    $ALHC
    $ALLR
    $ARDX

    CompanyDatePrice TargetRatingAnalyst
    Tandem Diabetes Care Inc.
    $TNDM
    2/23/2026$50.00Hold → Buy
    Lake Street
    Tandem Diabetes Care Inc.
    $TNDM
    2/20/2026$30.00Underperform → Neutral
    BofA Securities
    Tandem Diabetes Care Inc.
    $TNDM
    1/27/2026$25.00Buy
    TD Cowen
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Tandem Diabetes Care Inc.
    $TNDM
    12/16/2025$30.00Neutral → Outperform
    Robert W. Baird
    CG Oncology Inc.
    $CGON
    12/11/2025$70.00Outperform
    Wedbush
    CG Oncology Inc.
    $CGON
    11/24/2025Buy
    Truist
    Alignment Healthcare Inc.
    $ALHC
    11/24/2025$20.00Neutral → Overweight
    Analyst
    More analyst ratings

    $AEON
    $ALHC
    $ALLR
    $ARDX
    SEC Filings

    View All

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    2/27/26 4:06:08 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by CG Oncology Inc.

    S-8 - CG Oncology, Inc. (0001991792) (Filer)

    2/27/26 9:08:16 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by CG Oncology Inc.

    10-K - CG Oncology, Inc. (0001991792) (Filer)

    2/27/26 9:00:54 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tandem Diabetes Care upgraded by Lake Street with a new price target

    Lake Street upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $50.00

    2/23/26 8:30:19 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by BofA Securities with a new price target

    BofA Securities upgraded Tandem Diabetes Care from Underperform to Neutral and set a new price target of $30.00

    2/20/26 8:21:03 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    TD Cowen resumed coverage on Tandem Diabetes Care with a new price target

    TD Cowen resumed coverage of Tandem Diabetes Care with a rating of Buy and set a new price target of $25.00

    1/27/26 8:50:26 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $260,621 worth of shares (41,666 units at $6.25), decreasing direct ownership by 1% to 1,836,153 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/25/26 4:13:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Werner Robert F. sold $79,080 worth of shares (1,693 units at $46.71), decreasing direct ownership by 3% to 55,045 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/25/26 4:05:19 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Laponis Adam sold $97,390 worth of shares (2,085 units at $46.71), decreasing direct ownership by 2% to 128,291 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/25/26 4:05:17 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

    PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029 IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates. "In the coming month

    2/27/26 8:30:00 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics

    Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDARaises health plan membership guidance by 2,000 at the midpoint and introduces 2026 revenue guidance of $5.14 billion to $5.19 billion, representing 30%-31% growth year-over-year, and adjusted EBITDA of $133 million to $163 millionEarns recognition on the 2026 Fortune World's Most Admired Companies™ list, underscoring the company's innovative approach to senior health care ORANGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC),

    2/26/26 4:01:00 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Liu Brian Guan-Chyun bought $49,999,983 worth of shares (1,515,151 units at $33.00) (SEC Form 4)

    4 - CG Oncology, Inc. (0001991792) (Issuer)

    9/15/25 8:32:19 AM ET
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Financials

    Live finance-specific insights

    View All

    Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics

    Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDARaises health plan membership guidance by 2,000 at the midpoint and introduces 2026 revenue guidance of $5.14 billion to $5.19 billion, representing 30%-31% growth year-over-year, and adjusted EBITDA of $133 million to $163 millionEarns recognition on the 2026 Fortune World's Most Admired Companies™ list, underscoring the company's innovative approach to senior health care ORANGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC),

    2/26/26 4:01:00 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial and Strategic Highlights Achieved record quarterly sales: Worldwide sales of $290.4 million United States sales of $210.5 million Worldwide pump shipments of 38,000 United States pump shipments of 27,000 Delivered meaningful operational improvement: Record quarterly gross margin of 58% Operating income of $8.3 million, or 3% of sales Net loss of $0.6 million with posi

    2/19/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alignment Healthcare Inc.

    SC 13G/A - Alignment Healthcare, Inc. (0001832466) (Subject)

    11/14/24 5:57:27 PM ET
    $ALHC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by AEON Biopharma Inc.

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    11/14/24 5:05:14 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $AEON
    $ALHC
    $ALLR
    $ARDX
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Changes to Board of Directors

    MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer she served as President, Chairman, and as an independent director. She has served as a director of LogProstyle since September 2024, as an Executive Director of Akanda Corporation since Ju

    1/23/26 4:40:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care